Business
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France, May 27, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
About this update from Aelis Farma Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/2b7e76d6e49dcfccca17d8d135052ec9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hv5ckxHYwG54yPya684DHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2b7e76d6e49dcfccca17d8d135052ec9","width":480,"height":252}},"lazy":false},{"type":"text","content":"BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.","length":333,"tagName":"p"},{"type":"text","content":"Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors.","length":163,"tagName":"p"},{"type":"text","content":"With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors.","length":448,"tagName":"p"},{"type":"text","content":"Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors.","length":81,"tagName":"p"},{"type":"text","content":"Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company’s website within the legal time frame.","length":169,"tagName":"p"},{"type":"text","content":"About AELIS FARMA","length":17,"tagName":"p"},{"type":"text","content":"Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid syst...